Mitchell Sabloff

Head of the Leukemia Program

Ottawa Hospital

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Mitchell Sabloff is the Head of the Leukemia Program at the Ottawa Hospital in Canada. His research focuses on the management and treatment outcomes of leukemia, including the impact of donor characteristics on transplant outcomes, the quality of leukemia care, and the ethical considerations surrounding biobanking in clinical research. He has authored numerous articles addressing critical issues such as tumor lysis syndrome, frailty in myelodysplastic syndromes, and novel salvage therapies for refractory leukemia.

Articles (12)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Philip Berardi

Physician/Associate Professor

Ottawa Hospital Research Institute

CANADA

View details

Muhammad Bilal Abid

UNITED STATES

View details

Jill Fulcher

Assistant Professor, Clinical Hematologist

University of Ottawa Faculty of Medicine

CANADA

View details

David S Allan

University of Ottawa

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mitchell Sabloff

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Incidence of Tumour Lysis Syndrome in Patients with Acute Myeloid Leukemia During Initiation of Therapy with Azacitidine and Venetoclax: A Retrospective Chart Review from a Canadian Single-Centre Perspective

Patient and Healthcare Professional Reflections on Consenting for Extra Bone Marrow Samples to a Biobank for Research—A Qualitative Study

Developing Organizational Requirements to Standardize Delivery and Improve Quality of Acute Leukemia Care in Ontario

Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia

Younger Matched Unrelated Donors Confer Decreased Relapse Risk Compared to Older Sibling Donors in Older Patients with B Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes

Can GCSF-stimulated donor lymphocyte infusions improve outcomes for relapsed disease following allogeneic hematopoietic cell transplantation? A systematic review and meta-analysis

Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia

Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on?

Selecting the optimal targeted therapy for relapsed B-acute lymphoblastic leukemia

An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes

Collaborators (4)

Philip Berardi

Muhammad Bilal Abid

Jill Fulcher

David S Allan

Make your next move.